Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Subscribe To Our Newsletter & Stay Updated
